Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone is linked to reduced ischemic stroke risk in select patients with nonvalvular AF.

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

Cardiologist Dr. Josiah Brown, specializing in minimally invasive therapies, is the newest team member at Alaska Heart & ...

(JAMA Cardiology) Five-year results from the Amulet IDE trial suggested similar performance of the Amulet and Watchman 2.5 ...

Background: Percutaneous left atrial appendage occlusion (pLAAO) is widely used procedure as an alternative to oral anticoagulants in patients with atrial fibrillation at increased risk of bleeding or ...

Background: Left Atrial Appendage (LAA) Occlusion with Amulet has shown promising results in achieving complete closure with minimal periprocedural leak. Amulet’s dual-sealed technology and numerous ...

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Left atrial appendage closure is a mechanical alternative to anticoagulation, but data regarding its use after atrial fibrillation ablation are lacking. We conducted an international randomized ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.